Fibromyalgia Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Tonix Pharma, UCB Biopharma SRL, GlaxoSmithKline, Astellas Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Fibromyalgia pipeline constitutes 10+ key companies continuously working towards developing 10+ Fibromyalgia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Fibromyalgia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Fibromyalgia Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Fibromyalgia Market.


Some of the key takeaways from the Fibromyalgia Pipeline Report:

Companies across the globe are diligently working toward developing novel Fibromyalgia treatment therapies with a considerable amount of success over the years. 

Fibromyalgia companies working in the treatment market are Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, Pierre Fabre Medicament, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial – Portela C S.A, and others, are developing therapies for the Fibromyalgia treatment 

Emerging Fibromyalgia therapies in the different phases of clinical trials are- TNX102 SL, Rozanolixizumab, Paroxetine CR, Lacosamide, milnacipran, Rotigotine, Duloxetine, Saizen®, NYX-2925, ASP8062, Quetiapine, D-Ribose Powder, ESL 400, and others are expected to have a significant impact on the Fibromyalgia market in the coming years.  

In January 2024, Tonix Pharmaceuticals has announced further positive safety and tolerability findings for TNX-201, an investigational therapy, from a subsequent Phase III study focused on fibromyalgia. The topline results of the Phase III RESILIENT trial (NCT05273749), unveiled in December 2023, demonstrated the trial’s success in achieving its predefined primary endpoint by notably alleviating daily pain compared to a placebo among fibromyalgia patients. Moreover, supplementary safety and tolerability assessments indicated that TNX-201 did not lead to elevated systolic or diastolic blood pressure or changes in body weight. Notably, in the Changes in Sexual Functioning Questionnaire (CSFQ-14), female participants receiving TNX-102 exhibited higher CSFQ-14 scores, suggesting potential improvements in sexual function compared to those on placebo.

In November 2023, Tonix Pharmaceuticals has completed the clinical phase of the Phase III RESILIENT trial for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6mg, aimed at managing fibromyalgia. This multicenter trial, conducted across 33 sites in the US, enrolled 457 patients in a double-blind, placebo-controlled setting to assess the safety and efficacy of TNX-102 SL. The study involved a two-week run-in period where participants were randomly assigned to receive either TNX-102 SL 2.8mg or a placebo. The trial’s objective was to evaluate TNX-102 SL’s potential in managing fibromyalgia symptoms, marking a significant step in advancing treatment options for this challenging condition. 


Fibromyalgia Overview

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive issues. Its exact cause is unknown, but it’s believed to involve a combination of genetic, environmental, and psychological factors. Common symptoms include widespread pain, tenderness in specific areas of the body known as tender points, fatigue, sleep disturbances, cognitive difficulties (often referred to as “fibro fog”), and mood disorders such as depression and anxiety.


Get a Free Sample PDF Report to know more about Fibromyalgia Pipeline Therapeutic Assessment-


Emerging Fibromyalgia Drugs Under Different Phases of Clinical Development Include:

TNX102 SL: Tonix Pharmaceutical

Rozanolixizumab: UCB Biopharma SRL

Paroxetine CR: GlaxoSmithKline

Lacosamide: UCB Pharma

milnacipran: Pierre Fabre Medicament

Rotigotine: UCB Pharma

Duloxetine: Eli Lilly and Company

Saizen®: Merck

TNX-102 SL: Tonix Pharmaceuticals, Inc.

NYX-2925: Aptinyx

ASP8062: Astellas Pharma

Quetiapine: AstraZeneca

D-Ribose Powder: RiboCor, Inc.

ESL 400: Bial – Portela C S.A


Fibromyalgia Route of Administration

Fibromyalgia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 







Fibromyalgia Molecule Type

Fibromyalgia Products have been categorized under various Molecule types, such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody



Gene therapy


Fibromyalgia Pipeline Therapeutics Assessment

Fibromyalgia Assessment by Product Type

Fibromyalgia By Stage and Product Type

Fibromyalgia Assessment by Route of Administration

Fibromyalgia By Stage and Route of Administration

Fibromyalgia Assessment by Molecule Type

Fibromyalgia by Stage and Molecule Type


DelveInsight’s Fibromyalgia Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration


Further Fibromyalgia product details are provided in the report. Download the Fibromyalgia pipeline report to learn more about the emerging Fibromyalgia therapies


Some of the key companies in the Fibromyalgia Therapeutics Market include:

Key companies developing therapies for Fibromyalgia are – Eli Lilly and Company, AbbVie, Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Sanofi, GlaxoSmithKline plc., Pfizer, Inc., Bayer AG, TONIX Pharmaceuticals Holdings Corp, Virios Therapeutics, Inc., Aptinyx Inc., FSD Pharma, and others.


Fibromyalgia Pipeline Analysis:

The Fibromyalgia pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Fibromyalgia with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fibromyalgia Treatment.

Fibromyalgia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Fibromyalgia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fibromyalgia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Fibromyalgia drugs and therapies


Scope of Fibromyalgia Pipeline Drug Insight    

Coverage: Global

Key Fibromyalgia Companies: Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, Pierre Fabre Medicament, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial – Portela C S.A, and others

Key Fibromyalgia Therapies: TNX102 SL, Rozanolixizumab, Paroxetine CR, Lacosamide, milnacipran, Rotigotine, Duloxetine, Saizen®, NYX-2925, ASP8062, Quetiapine, D-Ribose Powder, ESL 400, and others

Fibromyalgia Therapeutic Assessment: Fibromyalgia current marketed and Fibromyalgia emerging therapies

Fibromyalgia Market Dynamics: Fibromyalgia market drivers and Fibromyalgia market barriers 


Request for Sample PDF Report for Fibromyalgia Pipeline Assessment and clinical trials


Table of Contents

1. Fibromyalgia Report Introduction

2. Fibromyalgia Executive Summary

3. Fibromyalgia Overview

4. Fibromyalgia- Analytical Perspective In-depth Commercial Assessment

5. Fibromyalgia Pipeline Therapeutics

6. Fibromyalgia Late Stage Products (Phase II/III)

7. Fibromyalgia Mid Stage Products (Phase II)

8. Fibromyalgia Early Stage Products (Phase I)

9. Fibromyalgia Preclinical Stage Products

10. Fibromyalgia Therapeutics Assessment

11. Fibromyalgia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Fibromyalgia Key Companies

14. Fibromyalgia Key Products

15. Fibromyalgia Unmet Needs

16 . Fibromyalgia Market Drivers and Barriers

17. Fibromyalgia Future Perspectives and Conclusion

18. Fibromyalgia Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart